• Home
  • Latest
  • Coins2Day 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Debate heats up over using an anti-malaria drug for COVID-19

By
Deb Riechmann
Deb Riechmann
,
Zeke Miller
Zeke Miller
and
The Associated Press
The Associated Press
Down Arrow Button Icon
By
Deb Riechmann
Deb Riechmann
,
Zeke Miller
Zeke Miller
and
The Associated Press
The Associated Press
Down Arrow Button Icon
April 6, 2020, 11:45 AM ET

President Donald Trump and members of his administration are growing emphatic in promoting an anti-malaria drug not yet officially approved for fighting COVID-19, even though scientists say more testing is needed before it’s proven safe and effective against the virus.

Trump trade adviser Peter Navarro promoted the drug, hydroxychloroquine, in a television interviews Monday, a day after Trump publicly put his faith in the drug to lesson the toll of the coronavirus pandemic.

“What do I know, I’m not a doctor,” Trump told reporters Sunday. “But I have common sense.”

The administration’s promotion of the drug comes after a heated Situation Room meeting of the White House’s coronavirus task force on Saturday, in which Navarro challenged the top U.S. Infectious disease expert Dr. Anthony Fauci over his concerns about recommending the drug based only on unscientific anecdotal evidence.

Navarro, who has no formal medical training, erupted at Fauci, raising his voice and claiming that the reports of studies he collected were enough to recommend the drug widely, according to a person familiar with the exchange who spoke on the condition of anonymity to describe the Situation Room blow-up.

Fauci has repeatedly said that current studies provide only anecdotal findings that the drug works. Navarro told CNN on Monday: “I would have two words for you: ‘second opinion.’”

Hydroxychloroquine is officially approved for treating malaria, rheumatoid arthritis and lupus, but not COVID-19. Small, preliminary studies have suggested it might help prevent the new coronavirus from entering cells and possibly help patients clear the virus sooner.

Two reports gave mixed results. A series of 11 patients in France found that an antibiotic-malaria drug combo did not improve how fast patients cleared the virus or their symptoms. Researchers in China reported that cough, pneumonia and fever seemed to improve sooner among 31 patients given hydroxychloroquine compared to 31 others who did not get the drug, but fewer people in the comparison group had cough or fevers to start with.

Doctors are already prescribing the malaria drug to patients with COVID-19, a practice known as off-label prescribing. But Fauci has said more testing is needed before it’s clear that the drug works against the coronavirus and is safe for COVID-19 patients.

Navarro told “Fox & Friends” that doctors in New York hospitals are already giving out the drug to COVID-19 patients and that health care workers are taking it in hopes it will protect them from being infected. He said the weekend standoff with Fauci was about whether the administration should take 29 million doses of the drug in FEMA warehouses and send them to hard-hit cities.

“The media is trying to blow it up as a big big debate, but I can tell you that within the room the decision was a sound one, and it was unanimous,” Navarro said.

Asked about his credentials for pushing the drug, Navarro cited his doctorate in social science.

“In the fog of war, we might take more risks than we otherwise would. And, given the track record of the drug over many many years in treating malaria that there are side effects but it’s been used a lot in lesser doses, the decisions’s been made by many doctors to prescribe it,” Navarro said. “If it saves lives, that’s a beautiful thing…I think history will judge who’s right on this debate. I’d bet on President Trump’s intuition on this one.”

Trump has been enthusiastically supporting the drug, and he announced Sunday that his administration has amassed 29 million doses for distribution to areas of the country hard-hit by the coronavirus.

“There’s a study out there that says people that have lupus haven’t been catching this virus,” Trump said at a Saturday briefing on the virus. “You know, maybe it’s true, maybe it’s not. … There’s also other studies … that the malaria countries … have very little of this virus.”

Trump said he would likely take the drug. “I may take it. OK? I may take it. And I’ll have to ask my doctors about that, but I may take it.”

Administration officials say Trump’s embrace of the drug stems from his desire to provide “hope” for the American people as the death toll mounts and he looks to avoid political consequences from the outbreak.

For most people, the virus causes mild or moderate symptoms, such as fever and cough that clear up in two to three weeks. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia, and death.

More coronavirus coverage from Coins2Day:

—Millions won’t be able to pay their bills this month. What financial experts advise
—What small businesses applying to the SBA’s Paycheck Protection Program need to know
—The worst part of losing 10M jobs in 2 weeks? The real number may be much higher
—Why the U.S. Is changing its mind on coronavirus face masks
—Americans face hunger crisis as SNAP benefits are harder for some to get
—Tax-exempt student loan assistance is now law. It’s time to make it permanent
—Hospitals are running low on the most critical supply of all: oxygen
—PODCAST: Two health care CEOs on why coronavirus tests and vaccines are the ammunition needed to fight COVID-19
—VIDEO: 401(k) withdrawal penalties waived for anyone hurt by COVID-19

Subscribe to Outbreak, a daily newsletter roundup of stories on the coronavirus pandemic and its impact on global business. It’s free to get it in your inbox.

About the Authors
By Deb Riechmann
See full bioRight Arrow Button Icon
By Zeke Miller
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

succession
SuccessFamily
How not to say that thing you’ll regret forever: 3 rules for family conversations about money 
By Glenn KurlanderJanuary 28, 2026
3 hours ago
reem
Commentaryhunger
How to fight child hunger in a time of foreign aid cuts
By Reem Alabali Radovan, Rajiv J. Shah and Mads Krogsgaard ThomsenJanuary 28, 2026
7 hours ago
People walk outside of a WeWork office building in London.
Future of WorkOffice Culture
Amazon and JPMorgan led the Coins2Day 500 in returning to the office 5 days a week. Now they’re leading a coworking comeback
By Jacqueline MunisJanuary 27, 2026
20 hours ago
Healthbeauty
5 Best Red Light Therapy Panels of 2026: Personally Tested
By Christina SnyderJanuary 27, 2026
20 hours ago
Graphic reads: Coins2Day Titans and Disruptors of Industry with Albert Bourla, CEO of Pfizer, Hosted by Alyson Shontell (both pictured).
C-SuiteCoins2Day 500: Titans and Disruptors of Industry
Pfizer CEO Albert Bourla stared down the COVID-19 pandemic. Now he has his eyes set on cancer 
By Coins2Day EditorsJanuary 27, 2026
1 day ago
Palantir CEO Alex Karp during an interview at the 2026 World Economic Forum in Davos, Switzerland.
InnovationImmigration
Palantir/ICE connections draw fire as questions raised about tool tracking Medicaid data to find people to arrest
By Tristan BoveJanuary 26, 2026
2 days ago

Most Popular

placeholder alt text
Commentary
Yes, you're getting a bigger tax refund. Your kids won't thank you for the $3 trillion it's adding to the deficit
By Daniel BunnJanuary 26, 2026
2 days ago
placeholder alt text
Personal Finance
Current price of silver as of Tuesday, January 27, 2026
By Joseph HostetlerJanuary 27, 2026
1 day ago
placeholder alt text
Success
Despite running $75 billion automaker General Motors, CEO Mary Barra still responds to ‘every single letter’ she gets by hand
By Preston ForeJanuary 26, 2026
2 days ago
placeholder alt text
Economy
An unusual Fed ‘rate check’ triggered a free fall in the U.S. dollar and investors are fleeing into gold
By Jim EdwardsJanuary 26, 2026
2 days ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, January 26, 2026
By Joseph HostetlerJanuary 26, 2026
2 days ago
placeholder alt text
Success
As AI wipes out desk jobs, Citigroup CEO Jane Fraser says the company is training 175,000 employees to ‘reinvent themselves’ before their roles change forever
By Emma BurleighJanuary 27, 2026
1 day ago

© 2026 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.